Journal for Research in Applied Sciences and Biotechnology
www.jrasb.com

ISSN: 2583-4053
Volume-1 Issue-5 || December 2022 || PP. 102-109
https://doi.org/10.55544/jrasb.1.5.11

A Comprehensive Study on Anthemintic Activity of Some Herbal Plants and Its Essential Oil

Ranjan Raj[1] and Ashna Kohli[2]
[1]Research scholar, department of Pharmacy, Guru Nanak College of Pharmaceutical Sciences, Dehradun-248007, Uttarakhand, INDIA
[2]Associate Professor, Department of Pharmacology, Guru Nanak College of Pharmaceutical Sciences, Dehradun-248007, Uttarakhand, INDIA.

[1]Corresponding Author: ranjanrajbth2000@gmail.com

www.jrasb.com || Vol. 1 No. 5 (2022): December Issue

Received: 05-11-2022	**Revised:** 26-11-2022	**Accepted:** 06-12-2022

ABSTRACT

It is an interesting opportunity to repurpose the medication by using it in conjunction with other treatments that function in a variety of different ways in order to combat helminthic infections and the diseases they cause. In this article, we emphasised how the usage of antioxidants, either alone or in conjunction with anthelmintic drugs, might reduce the chance of developing infection-related malignancies as well as tissue damage and infection-related issues. As a result, antioxidants have the potential to be utilised as a supportive strategy throughout the treatment process in order to reduce the possibility of undesirable effects. This results in a more complex immune interplay that has not yet been investigated. Deworming and supplementing the diet with iron-rich nutrients have been suggested as treatments for patients with podoconiosis who live in resource-poor conditions. Additionally, it is believed that hookworm infection may aid to decrease inflammatory reactions. However, due to the unmistakable connection that exists between a non-infectious and an infectious disease, it is possible for a situation to arise in which the treatment of one disease condition during a co-infection either makes the other disease condition worse or is mitigated by the impairment brought on by the other disease condition. We provide more detail on the immunopathogenesis of podoconiosis and investigate the potential immunological dynamics of hookworm co-infection in the immunopathology of podoconiosis with the goal of better managing the disease and eventually eliminating it. This work is being done in the context of the immunopathology of podoconiosis.

Keywords- Essential oil, helminthic, infections, hookworm.

I. INTRODUCTION

Helminths, a class of worms, are a major threat to animal health all over the world. Parasites can still cause problems for domestic animals, but keeping pastures in good shape can lessen their impact. The majority of government spending on animal health in some countries goes toward the purchase of pharmaceutical anthelmintics, which are used frequently in the treatment of helminthiasis. Because of the general lack of antiparasitic immunizations, anthelmintic drugs are now the cornerstone for the treatment of illness caused by veterinary helminths, and they will likely remain so for the foreseeable future. Over 95% parasite clearance, a generally good safety margin, a wide range of activity, and affordable pricing have all contributed to the astounding success of chemical treatment of parasites in animals over the past 50 years. Unfortunately, the widespread use of these medications has led to a dramatic increase in anthelmintic resistance (AR), especially among the gastrointestinal nematodes found in cattle, sheep, goats, and horses. [2] The alarming spread of AR among livestock parasites is a global threat to animal health and production. [3] Antihelmintics for small ruminants fall into three categories: benzimidazoles (BZs), macrocyclic lactones (MLs), and cholinergic agonists (especially levamisole; LEV). Every class of anthelmintic has been linked to AR. 2 Resistance to a

Journal for Research in Applied Sciences and Biotechnology
www.jrasb.com

ISSN: 2583-4053
Volume-1 Issue-5 || December 2022 || PP. 102-109
https://doi.org/10.55544/jrasb.1.5.11

drug appears to emerge in a time frame of less than ten years after its initial release. There are numerous factors that could influence the development of AR, including the host, the parasite, the anthelmintic used, animal management practises, and weather patterns.[4] As a result, it's more difficult to create control and prevention strategies, which may need to be tailored to different forms of animal production. The development of AR is complicated by a number of issues, such as the challenge of creating new anthelmintics and reverting resistant strains into susceptible ones. 5 Despite the growing problem of AR as a result of the widespread use of anthelmintics, alternative methods of managing helminth infections have not yet been established. Conducting routine AR detection and studying the risk factors and mechanisms of anthelmintic resistance are both crucial in stopping the spread of resistant parasites. [5]The primary goal of this review is to provide clarity on AR, including its causes, progression, diagnostic tools, and preventative measures. Due to the substantial productivity loss it causes, helminthiasis is among the most significant animal illnesses. An increased incidence of pneumonia, eosinophilia, anaemia, and malnutrition are only some of the health problems that can be brought on by exposure to helminths. Since healthcare is generally poor in developing nations, this illness is more common there [1]. However, helminth resistance to anthelmintics is becoming an increasing problem, hence it has been suggested that anthelmintic activity in medicinal herbs be evaluated [2, 3]. Plants can be used to create a herbal anthelmintic [4, 5].

1.1. Epidermiology Evidence of Helminth with human

The impacts of the human helminth parasite family are pervasive among the world's lowest communities. The two most prevalent sub-groups of helminths are nematodes (or roundworms) and trematodes (or flukes). While lymphatic filariasis (LF) and onchocerciasis are brought on by filarial worms, examples of soil-transmitted helminths (STH) include Ascaris lumbricoides, Trichuris trichiura, Necator americanus, and Ancylostoma duodenale. The three species that cause schistosomiasis are among the latter group (Schistosoma mansoni, Schistosoma haematobium and Schistosoma japonicum). According to one study, there are approximately 1.5 billion intestinal nematode infections worldwide [1]250 million individuals are thought to have schistosomiasis, 36 million to have LF, and 30 million to have onchocerciasis worldwide [2]. Even while helminth infections seldom result in death, they are associated with substantial morbidity, particularly in children [3]. Certain chronic helminth infections, such as bladder cancer (S. haematobium), anaemia (hookworm), and asthma, have been associated to noncommunicable diseases [4]. (A. lumbricoides). About 12 million DALYs are lost each year as a result of helminth infections [2], with STH (5.18 million) being responsible for the great majority of these losses [1]. The world's two regions with the highest infection rates are Sub-Saharan Africa and Southeast Asia [2]. Although WHO treatment guidelines vary depending on the type of helminth, the majority are currently focused on lowering mortality (although elimination programmes are in operation for the filarial infections). [8]



Fig 1: Life cycles of the bugs called opisthorchiids and schistosomes (green). To complete their complex life cycles, both parasites need two or more hosts. According to research published in, eating raw fish carrying metacercariae is the main way to contract Opisthorchis spp (A). Metacercariae are excystted in the duodenum after ingestion, and the juveniles then go through the biliary tract to grow, reproduce, and ultimately pass in the faeces. The parasite releases cercariae into the water after finishing its asexual reproductive cycle inside the snail, where they swim to and infect fish. (B) When human skin comes into contact with water containing the parasite's cercariae, they contract schistosomes. These larvae enter the body through a break in the skin, lose their tails in the dermis, and then mature into the schistosomulum stage, which lives inside the circulatory system. The schistosomes develop into adults that dwell in the venous blood of the intestines or pelvic organs after a few weeks. Adult worms expel their young after mating. Fresh water causes the eggs to hatch and release miracidia, which infect vulnerable snails and finish the life cycle.

Pharmaceutical companies, funders, endemic nations, and non-governmental organisations (NGOs) came together in London in 2012 to make a commitment to eradicating 10 Neglected Tropical Diseases (NTDs) by 2020 [5]. While LF elimination globally is the aim, onchocerciasis in Latin America and schistosomiasis in the Western Pacific Region also have comparable objectives (schistosomiasis). In all endemic countries, the target for STH treatment is to reach 75% treatment coverage among preschoolers and school-age children [6]. This indicates that 75% of all kids in these age groups who require treatment will get it frequently.

ISSN: 2583-4053
Volume-1 Issue-5 || December 2022 || PP. 102-109
https://doi.org/10.55544/jrasb.1.5.11

Some countries have already started transitioning from morbidity-controlling medicines to those targeted at totally eradicating the virus in anticipation of the 2022 deadline.[7] This transformation, which was previously observed through school-based deworming programmes, has mostly been attributed to mass drug administration (MDA) campaigns, in which entire communities are treated. However, since the prevalence of infection declines with each round of MDA, treating entire populations may no longer be the most effective or economical management technique. [8] On the other hand, focusing deworming efforts on particular people or groups based on traits that they share and who continue to be infected despite undergoing multiple cycles of treatment may be more successful [9]. This group of persons is adequately described by the word "predisposed." In addition to being more likely to regularly reintroduce infectious material into the neighbourhood, people who are genetically predisposed to getting an infection also have a higher likelihood of continuing transmission and raising the incidence rate even among individuals who have been treated. The transparency of the C. elegans nematode allows for easy observation of individual cells in both the developing and living organism. The worm can be thought of as a tube inside of a tube (Figure 2). [10,11,12,13,14] Strong muscles in the neck and intestines are covered by a protective cuticle that is comprised of a thick exoskeleton made of collagen. The gonad occupies the bulk of the human body's interior area. A bilobed gonad with tubes extending from each lobe to the midventral vulva and uterus is present in hermaphrodites. The worm can be either a male or a hermaphrodite. In the spermatheca, stored sperm are fertilised, and the uterus is where egg development starts. Males are in charge of fertilising hermaphrodites in terms of reproduction. The male sperm is likewise stored in the spermatheca, and it is this sperm that is most frequently employed during fertilisation.



Fig. 2: *Caenorhabditis elegans*. A composite diagram (*upper* panel) made by biorender software and photograph (*lower* panel) of the adult hermaphrodite with labeled body parts. Photograph click by Dr. ching D.

II. MATERIAL & METHODS

We searching from different source Like Pubmed, Google Scholar, NCBI, Scopus data base.

Keywords: "Herbs" "Anthemintic Activity" "Antioxidant properties"

2.1. Some Herbs Shows Anthemintic Activity

a. Picria fel-terrae Lour:

We found via this experiment that the extracts PE1 and PE2 of P. fel-terrae Lour. are particularly effective against the parasitic larval stages of H. contortus when used in vitro. Extract PE2 was, without fail, the most potent inhibitor of xL3 motility, despite the fact that there was no clear dose-dependent effect. This later extract slowed the movement of the worms, much like it did for the C. elegans it was tested on, even at the lowest dosage that was examined, which was 1 mg/ml. It is possible that the presence of different active constituents in these extracts is what explains the fact that PE1 and PE2 demonstrated distinct inhibitory properties on both the xL3 motility and the L4 development of H. contortus. [15] Alternatively, it is possible that the same constituents were present in different concentrations in different parts of the plant. It is noteworthy to observe that none of the plant extracts had any noticeable effect on the larvae at any of the time points that were tested. [16] It is possible that the active components in plant extracts have their greatest impact on H. contortus within the first 48 hours; however, it is also possible that I the active components in the extracts may have degraded during testing in the assay, rendering them ineffective against xL3s or L4s; or (iii) xL3s may have developed an acute "resistance" or used their defence mechanism to counteract some of the active constituent's effects. These are some of the probable explanations for the outcomes that were found (s),[17,18,19]

Experiments conducted during development and recovery revealed that PE1 was the sole factor that had a negative effect on the progression from xL3 to L4. In spite of the fact that both PE1 and PE4 had a discernible and unfavourable influence on the development of xL3s to L4, the majority of the PE4-treated larvae were able to recover and develop into L4s once the plant extract was withdrawn and replaced with LB. [20,21,22,23] Based on these findings, extract PE4 seems to have a reversible effect, but extract PE1 seems to have an irreversible effect on the motility of xL3 larvae and their growth. It's interesting to observe that monepantel showed a pattern that was identical to PE4 when it was tested at 20 M. Given how quickly worms can build up a resistance to treatment, it's not impossible that the powerful naturally occurring chemical PE4 will have the same effect (in as few as three generations). As a result, it is essential to do study on the H. contortus strain's resistance to infection.[24][25]

b. Carica Papaya:

In vitro anthelminthic tests showed that the effects of the extracts on the periods of paralysis and

Journal for Research in Applied Sciences and Biotechnology
ISSN: 2583-4053
Volume-1 Issue-5 || December 2022 || PP. 102-109
www.jrasb.com
https://doi.org/10.55544/jrasb.1.5.11

death were concentration-dependent. Increasing the concentration of the extract from 1 mg/ml to 5 mg/ml resulted in a significant decrease in both the paralysis time ($F(6,14) = 640.7$) and the death time ($F(6,14) = 1270$) that was measured. In general, it was found that the amount of time it took for the crude extracts to cause death and paralysis differed a considerable deal from one another. [27]When compared to albendazole, the results of post hoc testing on each of the plant extracts demonstrated that they considerably reduced the rates of both paralysis and mortality. This demonstrated that the seeds, bark, and leaves of the Carica papaya plant possessed significant anthelminthic effect in vitro against Pheretima posthuma. This conclusion was supported by the findings of the current investigation, and it is consistent with the findings of previous studies of the anthelminthic properties of seed, stem bark, and leaf latex. In addition to this, it was demonstrated that the effects of the plant parts that were investigated were superior to those of the widely prescribed anthelminthic medication known as albendazole when both were administered in the same dosages. [26,27,28,29,30]

III. SOME ESSENTIAL OIL USED

Blends of volatile hydrophobic secondary metabolites with a low molecular weight are what make up essential oils (EOs). [31][32][33] Cold pressing and, less commonly, steam distillation are used to extract them from plants. Aromatic alcohols, acids, esters, phenolics, ketones, aldehydes, and hydrocarbons are only a few of the hundreds of metabolites found in plants. Essential oils may have as many as three primary terpene or terpenoid components, accounting for as much as 30 percent of the oil. Bioactive compounds like terpenoids and phenylpropanoids isolated from EOs have found widespread application in a variety of fields, including pharmaceuticals, medicine, biology, and agriculture. Larvicidal, insecticidal, anthelmintic, and anticancer chemicals have been found in EOs. [34][35][36] They might even work against the insects that spread arboviruses. Even in the Middle Ages, the Arabs were using EOs to cure a wide variety of ailments. Antibacterial, anti-inflammatory, analgesic, spasmolytic, sedative, and local anaesthetic properties of Eos were discussed by Bakkali et al. Research on EOs and its constituents has lately acquired importance due to the good biological effects that have been proved to be caused by EOs. Because of their lipophilic nature, essential oils can pass through the blood-brain barrier and the membranes of parasites, providing new opportunities for treating the second stage of parasitic disorders. Enhanced nitric oxide production in the host, lower parasite susceptibility to reactive oxygen species, and increased lipid peroxidation due to oxidative stress from EOs all pose threats to the parasite's cell membranes.[37,38,39,40] Essential oils can be used to treat protozoa, helminths, and neglected tropical diseases in animals.

a. *Terpenes*

Despite the fact that terpenes have been used as anthelmintics by humans for over a century, very little in-depth study has been conducted on the topic. Here, we examine the dose-response effectiveness of several terpenes against an extensive collection of STNs spanning numerous evolutionary lineages. Terpenes have the potential for a number of improvements, such as enhanced pharmacodynamics through the use of innovative formulation techniques and a wider range of efficacy (parasite resistance is more difficult to develop against terpenes) (e.g., encapsulation and enteric coated capsules to protect premature release and absorption in the stomach). [41] Hydrophobic terpenes are captured in YPs when they passively diffuse through the YP shell into the hydrophobic interior, filling the hollow cavity as a droplet of terpene oil. A few of the benefits of terpene encapsulation in YPs for in vitro testing are a high terpene load level (50 percent terpene w/w), water-susceptible terpene formulations without surfactants, high terpene bioavailability, and delayed terpene release. Tests on YP-terpenes in vitro have shown that there are five different pharmacodynamic classes of terpenes, each of which is effective against either the hookworm A. ceylanicum or the whipworm T. muris. Terpenes' efficacy can be broken down into five categories: To summarise, it was found to be sluggish at lower concentrations (33–66 g/mL), slow at moderate–high concentrations (100–333 g/mL), rapid at high concentrations (333 g/mL), and fast at moderate–high concentrations (100–333 g/mL), and ineffective at the concentrations studied. Rapid terpene release from YPs can occur in as short as one to three hours due to the solubility of most fast-acting terpenes in water being greater than the dose tested. [42,43][44] The terpene-lipid interaction in YPs likely causes a delay in the release kinetics, which is why L-carvone is only fast-acting at extremely high concentrations. To get the necessary terpene dose release from YPs, the slow-acting at a moderate-high dose group terpenes require a longer incubation time (24 h). We discovered that terpenes (farnesol, nerolidol) that are notoriously water-insoluble can self-emulsify in YP-terpene aqueous solutions, leading in terpene release rates 20-30 times higher than their maximal solubility in water. Generally, T. muris showed less sensitivity to terpenes than A. ceylanicum. The fungus A. ceylanicum was killed in about one hour when treated with 200 g/mL of a fast-acting terpene, but T. muris required three times as long. [44] Moreover, in the second group, we were unable to locate any terpenes that exhibited activity against T. muris (high-dose, fast-acting). Comparative studies showed that other terpenes, including those found in A. ceylanicum, either took longer to function or were significantly less efficient than A. ceylanicum against whipworm. Upon testing various YP-terpenes against N. brasiliensis, it was shown that a concentration of 200 ng/mL of carvacrol, thymol, and cinnamic aldehyde was sufficient to cause total

ISSN: 2583-4053
Volume-1 Issue-5 || December 2022 || PP. 102-109
https://doi.org/10.55544/jrasb.1.5.11

worm incapacitation in 1 hour. Due to its likeness to human hookworms, this rat parasite will serve as a useful intestinal nematode/rodent laboratory model in our planned research on the efficacy of orally administered YP-terpenes. [45][46]

b. Sesquiterpenes

The class of molecules known as sesquiterpenes, which are terpenes with three isoprene units and a carbon number of 15, are the second most prevalent type of substance found in plant essential oils. [47] [48] Since the discovery of artemisinin, numerous other sesquiterpenes have been shown to possess characteristics that are effective against certain protozoa. - Caryophyllene is found in the essential oil (EO) of a number of plants, including Newbouldia laevis (36.08%) and Bidens sulphurea (10.23%), and it is effective in a mortality test against Schistosoma mansoni. In addition, an experiment for the development of larvae reveals that the essential oil of Pinus nigra Arn. subsp. pallasiana is beneficial against Echinococcus spp., but the essential oil of Plectranthus neochilus is effective against Strongyloides ratti. [49] [50] There are a variety of essential oils (EOs) that contain trans-caryophyllene, an ingredient that is helpful against Schistosoma mansoni. These include Baccharis trimera, Mentha x villosa, and others. The helminths Trichostrongylus spp., Haemonchus spp., Syphacia obvelata, and Aspiculuris tetraptera are all susceptible to (E)-caryophyllene, which can be found in a number of essential oils (EOs), including those derived from Ageratum conyzoides and Lippias idoides, in varying levels. (E)-cary The egg-hatching assay performed with H. contortus also demonstrates the efficacy of the caryophyllene oxide (50.26%) and copaene (10.58%) found in Lantana camara.

c. Alchol

In the initial phytochemical screening of the alcoholic extract, alkaloids, tannins, phenolic compounds, and steroids were discovered, whereas phenolic compounds and tannins were discovered in the aqueous extract. Both the alcoholic and aqueous extracts of B. montanum root exhibited significant anthelmintic properties at therapeutic concentrations. Both extracts showed anthelmintic effects in a dose-dependent manner, with the 100 mg/ml dosage causing the shortest time to paralysis (P) and death (D) for both worm types. In comparison to water-based extract, which accomplished the same thing in 9 and 30 minutes, alcohol-based B. montanum extract paralysed and killed P. posthuma in 10 minutes. Standard drug piperazine citrate produced same effects at 21 and 59 minutes. [51]

d. Aldehydes

In the presence of ammonium acetate and glacial acetic acid, benzil was refluxed with a number of substituted aldehydes to yield a range of 2-substituted-4,5-diphenyl imidazoles 1a–j. The predicted structures of the synthesised compounds were verified using nuclear magnetic resonance spectroscopy, infrared spectroscopy, and mass spectrometry. The presence or absence of anthelmintic properties in compounds 1a–j was determined. The results showed that the compounds had paralysis times of 0.24 to 1.54 minutes and death times of 0.39 to 4.40 minutes at a concentration of 1% (m/V), compared to times for albendazole and piperazine citrate, two common medications, of 0.54 and 0.58 minutes and 2.16 and 2.47 minutes, respectively. [52-55] Five distinct compounds are available: 2-[2-hydroxyphenyl] 2-[3-methoxyphenyl]-4,5-diphenyl imidazole (1b) 4- and -4,5-diphenyl imidazole (1a) (2-Phenylethenyl) -4,5-dihydroimidazole (1c) (1c) 1-(4-fluorophenyl) -4,5-dihydroimidazole (1e) (1e) 2-[3-nitrophenyl]-1 gramme 0.5 grammes of 1-,2-dimethylbenzo[a]imidazole and -4,5-diimidazole The anthelmintic activity of -4,5-diphenyl imidazole (1h) was noteworthy when compared to the gold standard drugs.

e. Miscellaneous EO Components

Eucalyptus is one of many plant essential oils (EOs) that contain between 17 and 42% of 1,8-cineole (eucalyptol). This substance works well against other gastrointestinal nematodes in addition to H. contortus (sheep). Camphor and 1,8-cineole had the greatest killing power against H. contortus (16.65% and 34.56%, respectively). 1,8-cineole is present in Alpinia zerumbet EO along with p-cymene (22.56%) and 4-terpineol (17.43%), while it is present in Rosmarinus officinalis EO along with 2-bornanone (16.37%) and -pinene (14.76%). (sheep). [56] The anti-Echinococcus ingredients in Myrtus communis EO are a-pinene (24.7%), 1,8-cineole (19.6%), and linalool (12.6%). 1,8-cineole (32.71%) and eugenol (43.71%) from Ocimum gratissimum EO were both successful against H. contortus in an egg hatch assay. Caryophyllene oxide (50.26%) and copaene (10.58%), two components of Lantana camara's EO, are particularly effective at preventing the growth of H. contortus larvae and hatchlings. Borneol (18.61%) outperformed -elemene (10.87%) in the egg-hatching assay with H. contortus for Zanthoxylum simulans EO. There is action against H. contortus when piperitenone is extracted from Tagetes patula's EO (23.5% of the total; 40 g/mL, EC50, egg hatch assay). In a study by Ganza et al., it was discovered that dillapiole (76.2% of Piper aduncum's EOs) was effective against H. contortus (100 to 5720 g/mL, IC50). De Melo et al. demonstrated the activity of precocene I, a significant component (74.30%) of Ageratum conyzoides EO, using a mortality assay. When rotundifolone is employed in a mortality assay at doses between 10 and 100 g/mL, Schistosoma mansoni will be eliminated 79% of the time. We can conclude that EO effectiveness is significantly variable.[57] The assay methods, concentrations, and strains themselves all differ. Even when tested on the same species, it has been demonstrated that the chemical class of the components (monoterpene or phenylpropanoid) and the major functional groups have a substantial impact on the EC50 or IC50 values (aldehyde, ketone and alcohol). Since

ISSN: 2583-4053
Volume-1 Issue-5 || December 2022 || PP. 102-109
https://doi.org/10.55544/jrasb.1.5.11

cyclohexene-containing molecules differ significantly from phenylic compounds and alkenes, the carbon backbone appears to be crucial. [58] The experiments also revealed a differentiation between alkenes and phenylic compounds. This suggests that the chemical's bioactivity depends more on its overall structure than on any specific functional groups or other characteristics. Additionally, the ideal dose for each isomer can vary, which might indicate a distinct therapeutic target (rather than a physicochemical effect on membranes, as is often assumed).[59][60]

IV. CONCLUSION

In the coming years, molecular epidemiology techniques based on genome sequencing, possibly based on single nucleotide polymorphisms (SNPs), may be used to identify "who infects whom" and determine whether or not particular ethnic groups are more susceptible, revealing more about the underlying factors that contribute to susceptibility. This study supports the traditional or herbal healers' and indigenous peoples' use of Carica papaya, namely the seeds, as an anthelmintic agent for the treatment of helminthiasis or worm infestation. demonstrates in an in vitro setting how effective the essential oils from C. aurantifolia, A. nobile, and L. officinais are against the main stages of the parasite H. contortus. It emphasises the necessity to search among medicinal plants with promising chemical constituents for new potential anthelmintic drugs. The most promising EOs in this regard were those from the plants O. vulgare, F. vulgare, S. montana, two samples of T. vulgaris, and S. hortensis, which contain compounds such carvacrol, thymol, anethol, p-cymene, and y-terpinene. A second in vivo trial with altered settings (larger dosages, a different mode of application, or the use of encapsulating techniques) for samples tested in vivo (T. vulgaris EO and linalool:estragole combo), however, is necessary to achieve better efficacy in the field. The findings of this study, however, contribute to the expanding body of proof that botanical anthelmintics might be helpful in the control of sheep GINs. The results of this study could thus be used in the future to combat anthelmintic resistance.

REFERENCES

[1] Morgan E R, Aziz N-A A, Blanchard A, Charlier J, Charvet C, Claerebout E, Geldhof P, Greer A W, Hertzberg H, Hodgkinson J, et al. *Trends Parasitol.* 2019;35:52–71. doi: 10.1016/j.pt.2018.10.006.
[2] Hotez P J, Molyneux D H, Fenwick A, Kumaresan J, Sachs S E, Sachs J D, Savioli L. *N Engl J Med.* 2007;357:1018–1027. doi: 10.1056/nejmra064142.
[3] GBD 2016 DALYs and HALE Collaborators *Lancet.* 2017;390:1260–1344. doi: 10.1016/s0140-6736(17)32130-x.
[4] Hotez P. *PLoS Neglected Trop Dis.* 2007;1:e118. doi: 10.1371/journal.pntd.0000118.
[5] Molyneux D H, Dean L, Adekeye O, Stothard J R, Theobald S. *Parasitology.* 2018;145(13):1647–1654. doi: 10.1017/s0031182018000069.
[6] Pullan R L, Smith J L, Jasrasaria R, Brooker S J. *Parasites Vectors.* 2014;7:37. doi: 10.1186/1756-3305-7-37.
[7] Global Burden of Disease Study 2013 Collaborators *Lancet.* 2015;386:743–800. doi: 10.1016/s0140-6736(15)60692-4
[8] de Silva N R, Chan M S, Bundy D A. *Trop Med Int Health.* 1997;2:519–528. doi: 10.1046/j.1365-3156.1997.d01-320.x.
[9] de Silva N R, Guyatt H L, Bundy D A. *Trans R Soc Trop Med Hyg.* 1997;91:31–36. doi: 10.1016/s0035-9203(97)90384-9.
[10] Murray C J L, Vos T, Lozano R, Naghavi M, Flaxman A D, Michaud C, Ezzati M, Shibuya K, Salomon J A, Abdalla S, et al. *Lancet.* 2012;380:2197–2223. doi: 10.1016/s0140-6736(12)61689-4.
[11] Keiser J, Tritten L, Silbereisen A, Speich B, Adelfio R, Vargas M. *PLoS Neglected Trop Dis.* 2013;7:e2119. doi: 10.1371/journal.pntd.0002119.
[12] Hotez P, Whitham M. *Obstet Gynecol.* 2014;123:155–160. doi: 10.1097/aog.0000000000000025.
[13] Gardner J M, Grantham-Mcgregor S, Baddeley A. *Ann Trop Med Parasitol.* 1996;90(1):55–63. doi: 10.1080/00034983.1996.11813026. 16. Simeon D T, Grantham-McGregor S M, Callender J E, Wong M S. *J Nutr.* 1995;125:1875–1883. doi: 10.1093/jn/125.7.1875. Stephenson L S, Latham M C, Adams E J, Kinoti S N, Pertet A. *J Nutr.* 1993;123:1036–1046.
[14] *Progress Report 2000–2009 and Strategic Plan 2010–2020 of the Global Programme to Eliminate Lymphatic Filariasis: Halfway towards Eliminating Lymphatic Filariasis.* World Health Organization; 2010.
[15] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators *Lancet.* 2018;392:1789–1858. doi: 10.1016/s0140-6736(18)32279-7. McManus D P, Dunne D W, Sacko M, Utzinger J, Vennervald B J, Zhou X-N. *Nat Rev Dis Primers.* 2018;4(1):13. doi: 10.1038/s41572-018-0013-8.
[16] Hotez P. *PLoS Neglected Trop Dis.* 2007;1:e77. doi: 10.1371/journal.pntd.0000077.
[17] Marocco C, Bangert M, Joseph S A, Fitzpatrick C, Montresor A. *Trans R Soc Trop Med Hyg.* 2017;111:12–17. doi: 10.1093/trstmh/trx011.
[18] Bah Y M, Bah M S, Paye J, Conteh A, Saffa S, Tia A, Sonnie M, Veinoglou A, Amon J J, Hodges M H, et al. *Infect Dis Poverty.* 2019;8:41. doi: 10.1186/s40249-019-0553-5.

ISSN: 2583-4053
Volume-1 Issue-5 || December 2022 || PP. 102-109
https://doi.org/10.55544/jrasb.1.5.11

[19] Shumbej T, Menu S, Girum T, Bekele F, Gebru T, Worku M, Dendir A, Solomon A, Kahase D, Alemayehu M. *Res Rep Trop Med.* 2019;10:109–118. doi: 10.2147/rrtm.s208473.
[20] Freeman M C, Akogun O, Belizario V, Brooker S J, Gyorkos T W, Imtiaz R, Krolewiecki A, Lee S, Matendechero S H, Pullan R L, et al. *PLoS Neglected Trop Dis.* 2019;13:e0007201. doi: 10.1371/journal.pntd.0007201.
[21] *WHO Model List of Essential Medicines, 20th List.* World Health Organization; 2017.
[22] De Clercq D, Sacko M, Behnke J, Gilbert F, Dorny P, Vercruysse J. *Am J Trop Med Hyg.* 1997;57(1):25–30. doi: 10.4269/ajtmh.1997.57.25. Soukhathammavong P A, Sayasone S, Phongluxa K, Xayaseng V, Utzinger J, Vounatsou P, Hatz C, Akkhavong K, Keiser J, Odermatt P. *PLoS Neglected Trop Dis.* 2012;6:e1417. doi: 10.1371/journal.pntd.0001417.
[23] Moser W, Schindler C, Keiser J. *BMJ [Br Med J]* 2017;358:j4307. doi: 10.1136/bmj.j4307. Moser W, Schindler C, Keiser J. *Adv Parasitol.* 2019;103:91–115. doi: 10.1016/bs.apar.2018.08.002.
[24] Demeler J, Krüger N, Krücken J, von der Heyden V C, Ramünke S, Küttler U, Miltsch S, López Cepeda M, Knox M, Vercruysse J, et al. *PLoS One.* 2013;8:e70212. doi: 10.1371/journal.pone.0070212
[25] Geurden T, Hoste H, Jacquiet P, Traversa D, Sotiraki S, Frangipane di Regalbono A, Tzanidakis N, Kostopoulou D, Gaillac C, Privat S, et al. *Vet Parasitol.* 2014;201:59–66. doi: 10.1016/j.vetpar.2014.01.016. 33. Matamoros G, Rueda M M, Rodríguez C, Gabrie J A, Canales M, Fontecha G, Sanchez A. *Trop Med Infect Dis.* 2019;4:73. doi: 10.3390/tropicalmed4020073.
[26] Zuccherato L W, Furtado L F, da Silva Medeiros C, da Silva Pinheiro C, Rabelo É M. *PLoS Neglected Trop Dis.* 2018;12:e0006766. doi: 10.1371/journal.pntd.0006766.
[27] 35. Orr A R, Quagraine J E, Suwondo P, George S, Harrison L M, Dornas F P, Evans B, Caccone A, Humphries D, Wilson M D, et al. *Am J Trop Med Hyg.* 2019;100:351–356. doi: 10.4269/ajtmh.18-0727.
[28] Vercruysse J, Albonico M, Behnke J M, Kotze A C, Prichard R K, McCarthy J S, Montresor A, Levecke B. *Int J Parasitol: Drugs Drug Resist.* 2011;1:14–27. doi: 10.1016/j.ijpddr.2011.09.002.
[29] Brooker S, Clements A C A, Bundy D A P. Global Epidemiology, Ecology and Control of Soil-Transmitted Helminth Infections. In: Hay S I, Graham A, Rogers D J, editors. *Advances in Parasitology.* Vol. 62. Academic Press; 2006. pp. 221–261. ((Global Mapping of Infectious Diseases: Methods, Examples and Emerging Applications)). Ziegelbauer K, Speich B, Mäusezahl D, Bos R, Keiser J, Utzinger J. *PLoS Med.* 2012;9:e1001162. doi: 10.1371/journal.pmed.1001162. Partridge F A, Forman R, Willis N J, Bataille C J R, Murphy E A, Brown A E, Heyer-Chauhan N, Marinič B, Sowood D J C, Wynne G M, et al. *PLoS Neglected Trop Dis.* 2018;12:e0006487. doi: 10.1371/journal.pntd.0006487.
[30] 40. [Oct 29;2019];*WHO Strategy: Intestinal worms.* Available from: http://www.who.int/intestinal_worms/strategy/en/
[31] Olliaro P, Delgado-Romero P, Keiser J. *J Antimicrob Chemother.* 2014;69:863–870. doi: 10.1093/jac/dkt491
[32] Bagchus W M, Bezuidenhout D, Harrison-Moench E, Kourany-Lefoll E, Wolna P, Yalkinoglu O. *Clin Transl Sci.* 2019;12:66–76. doi: 10.1111/cts.12601. Doenhoff M J, Cioli D, Utzinger J. *Curr Opin Infect Dis.* 2008;21:659–667. doi: 10.1097/qco.0b013e328318978f
[33] Zwang J, Olliaro P L. *PLoS Neglected Trop Dis.* 2014;8(11):e3286. doi: 10.1371/journal.pntd.0003286. Crellen T, Walker M, Lamberton P H L, Kabatereine N B, Tukahebwa E M, Cotton J A, Webster J P. *Clin Infect Dis.* 2016;63:1151–1159. doi: 10.1093/cid/ciw506.
[34] Wang W, Wang L, Liang Y-S. *Parasitol Res.* 2012;111:1871–1877. doi: 10.1007/s00436-012-3151-z.
[35] McCreesh N, Nikulin G, Booth M. *Parasites Vectors.* 2015;8:4. doi: 10.1186/s13071-014-0617-0.
[36] Toor J, Alsallaq R, Truscott J E, Turner H C, Werkman M, Gurarie D, King C H, Anderson R M. *Clin Infect Dis.* 2018;66(Suppl 4):S245–S252. doi: 10.1093/cid/ciy001.
[37] World Health Organization *Wkly Epidemiol Rec.* 2019;94:457–470.
[38] King C L, Suamani J, Sanuku N, Cheng Y-C, Satofan S, Mancuso B, Goss C W, Robinson L J, Siba P M, Weil G J, et al. *N Engl J Med.* 2018;379:1801–1810. doi: 10.1056/nejmoa1706854.
[39] Singhal AK, Giri S, Kumar R. INVESTIGATION OF IN-VITRO ANTI-OXIDANT & ANTI-ULCER ACTIVITY OF ANGIOGENESIS LATIFOLIA ROXB (DHAVA). NEUROQUANTOLOGY. 2022 Sep;20(11):5680-6.v
[40] Bjerum C M, Ouattara A F, Aboulaye M, Kouadio O, Marius V K, Andersen B J, Weil G J, Koudou B G, King C L. *Clin Infect Dis.* doi: 10.1093/cid/ciz1050.
[41] *Guideline: Alternative Mass Drug Administration Regimens to Eliminate Lymphatic Filariasis.* World Health Organization; 2017
[42] Sharma R, Al Jayoussi G, Tyrer H E, Gamble J, Hayward L, Guimaraes A F, Davies J, Waterhouse D, Cook D A N, Myhill L J, et al. *Sci Rep.* 2016;6:23458. doi: 10.1038/srep23458.
[43] Mishra A, Singh Y, Singh R, Kumar R, Shukla S, Kumar R, Prajapati A, Rawat N, Kumar A, Pol SL, Pol SL. Ethano-pharmacology activity & Antioxidant activity of Centella asiatica Plant Parts. NEUROQUANTOLOGY. 2022 Oct;20(11):7562-72.
[44] Turner J D, Tendongfor N, Esum M, Johnston K L, Langley R S, Ford L, Faragher B, Specht S, Mand S,

ISSN: 2583-4053
Volume-1 Issue-5 || December 2022 || PP. 102-109
https://doi.org/10.55544/jrasb.1.5.11

Hoerauf A, et al. *PLoS Neglected Trop Dis.* 2010;4:e660. doi: 10.1371/journal.pntd.0000660.
[45] World Health Organization *Wkly Epidemiol Rec.* 2019;94:513–523
[46] Keshamma E, Kumar A, Jha R, Amle VS, Dudhate GS, Patel D, Saha P, Kumar R. Breast Cancer Treatment Relying on Herbal Bioactive Components. Journal for Research in Applied Sciences and Biotechnology. 2022 Oct 31;1(4):105-15..
[47] Tekle A H, Zouré H G M, Noma M, Boussinesq M, Coffeng L E, Stolk W A, Remme J H F. *Infect Dis Poverty.* 2016;5:66. doi: 10.1186/s40249-016-0160-7.
[48] Nicholls R S, Duque S, Olaya L A, López M C, Sánchez S B, Morales A L, Palma G I. *Parasites Vectors.* 2018;11(1):237. doi: 10.1186/s13071-018-2821-9.
[49] Guevara Á, Lovato R, Proaño R, Rodriguez-Perez M A, Unnasch T, Cooper P J, Guderian R H. *Parasites Vectors.* 2018;11:265. doi: 10.1186/s13071-018-2851-3.
[50] Opoku N O, Bakajika D K, Kanza E M, Howard H, Mambandu G L, Nyathirombo A, Nigo M M, Kasonia K, Masembe S L, Mumbere M, et al. *Lancet.* 2018;392:1207–1216. doi: 10.1016/s0140-6736(17)32844-1.
[51] Kuesel A C. *Int J Parasitol: Drugs Drug Resist.* 2016;6:272–286. doi: 10.1016/j.ijpddr.2016.04.002.
[52] Zhan B, Beaumier C M, Briggs N, Jones K M, Keegan B P, Bottazzi M E, Hotez P J. *Expert Rev Vaccines.* 2014;13:321–331. doi: 10.1586/14760584.2014.872035.
[53] Subramanian M, Keshamma E, Janjua D, Kumar D, Kumar R, Saha P, Gupta RK, Rao S. Quality Risk Management Approach for Drug Development and Its Future Prospectives. Journal for Research in Applied Sciences and Biotechnology. 2022 Aug 31;1(3):166-77.
[54] Tsuji N, Suzuki K, Kasuga-Aoki H, Matsumoto Y, Arakawa T, Ishiwata K, Isobe T. *Infect Immun.* 2001;69:7285–7292. doi: 10.1128/iai.69.12.7285-7292.2001.
[55] Dixon H, Little M C, Else K J. *Int J Parasitol.* 2010;40:683–693. doi: 10.1016/j.ijpara.2009.11.008.
[56] Wei J, Versteeg L, Liu Z, Keegan B, Gazzinelli-Guimarães A C, Fujiwara R T, Briggs N, Jones K M, Strych U, Beaumier C M, et al. *PLoS Neglected Trop Dis.* 2017;11:e0005769. doi: 10.1371/journal.pntd.0005769.
[57] Briggs N, Wei J, Versteeg L, Zhan B, Keegan B, Damania A, Pollet J, Hayes K S, Beaumier C, Seid C A, et al. *PLoS Pathog.* 2018;14:e1007273. doi: 10.1371/journal.ppat.1007273.
[58] Loukas A, Hotez P J, Diemert D, Yazdanbakhsh M, McCarthy J S, Correa-Oliveira R, Croese J, Bethony J M. *Nat Rev Dis Primers.* 2016;2:16088. doi: 10.1038/nrdp.2016.88.
[59] Riveau G, Deplanque D, Remoué F, Schacht A-M, Vodougnon H, Capron M, Thiry M, Martial J, Libersa C, Capron A. *PLoS Neglected Trop Dis.* 2012;6:e1704. doi: 10.1371/journal.pntd.0001704
[60] Lacerda M V G, Llanos-Cuentas A, Krudsood S, Lon C, Saunders D L, Mohammed R, Yilma D, Batista Pereira D, Espino F E J, Mia R Z, et al. *N Engl J Med.* 2019;380:215–228. doi: 10.1056/nejmoa1710775.